Biotech | January 20, 2026
DNA Nanorobots & AI could slash drug development times, Nanovery CEO says
DNA nanorobots—tiny, self-assembling machines capable of detecting diseases in blood samples within 2–4 hours
DNA nanorobots—tiny, self-assembling machines capable of detecting diseases in blood samples within 2–4 hours
Stevens succeeds Milton Boyer, who has stepped down as CEO but will remain closely involved with the business as an independent member of Kindeva’s Board of Directors
The expanded agreement significantly widens the scope of integrated services across the entire drug development lifecycle
India in the Changing Landscape of Life-Sciences Research & Development
LOTTE Biologics will provide advanced manufacturing services for monoclonal antibody intermediates and their conjugates
The Eugene facility, with more than 20 years of history, houses a 16,000-square-foot R&D lab and a newly constructed 30,000-square-foot manufacturing facility
UNLOXCYT is an evolution in checkpoint inhibition and is now available for the treatment of adults in the U.S. with mCSCC or laCSCC who are not candidates for curative surgery or curative radiation
The partnership aims to fuse Avantium’s breakthrough materials with Packamama’s expertise in low-emission, innovative wine bottles
The deal to acquire AT-01 (124-Iodine-evuzamitide) and AT-05 (PAR-Peptide + technetium-99m) underscores Bayer’s commitment to expanding in molecular imaging and advancing precision cardiology
The feature will be available across all Max Healthcare facilities, offering patients consistent and convenient access to services nationwide
Subscribe To Our Newsletter & Stay Updated
